ArticleFrontiers in immunology2026
Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fluoropyrimidines, including 5-fluorouracil (5-FU), capecitabine, tegafur, and trifluridine, are widely used anticancer agents, but their gastrointestinal toxicities remain clinically important. This study characterized fluoropyrimidine-associated adverse-event reporting signals across multiple pharmacovigilance databases and described epithelial-cell responses that may provide experimental context for gastrointestinal toxicity. Methods: Adverse-event reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Report database (JADER), and Canada Vigilance Adverse Reaction Database (CVARD) were analyzed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM) approaches. Time to onset (TTO) analysis was limited to FAERS because complete onset information was unavailable in JADER and CVARD. GES-1 gastric epithelial cells and NCM460 colonic epithelial cells were used for acute and 7-day repeated-exposure injury experiments. Additional representative-treatment experiments assessed fluorescein isothiocyanate (FITC)-dextran permeability and relative supernatant interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels. Results: Fluoropyrimidines showed gastrointestinal reporting signals with drug-specific reporting patterns. TTO analysis in FAERS showed an overall early-reporting pattern; the distribution of reports between days 181 and 360 was exploratory. Conclusion: This study identifies pharmacovigilance reporting signals and provides experimental evidence that fluoropyrimidine exposure is associated with epithelial injury, impaired barrier function, and epithelial inflammatory responses. The reporting signals do not estimate event frequency in treated populations or establish causality and require confirmation in exposure-adjusted studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.